thalidomide has been researched along with Rosacea in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Rosacea: A cutaneous disorder primarily of convexities of the central part of the FACE, such as FOREHEAD; CHEEK; NOSE; and CHIN. It is characterized by FLUSHING; ERYTHEMA; EDEMA; RHINOPHYMA; papules; and ocular symptoms. It may occur at any age but typically after age 30. There are various subtypes of rosacea: erythematotelangiectatic, papulopustular, phymatous, and ocular (National Rosacea Society's Expert Committee on the Classification and Staging of Rosacea, J Am Acad Dermatol 2002; 46:584-7).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our findings suggest thalidomide attenuates the inflammation and represses NF-κB activation in skin, which leads to assumptions that thalidomide may be a new therapeutic agent for rosacea." | 7.91 | Thalidomide ameliorates rosacea-like skin inflammation and suppresses NF-κB activation in keratinocytes. ( Chen, M; Chen, Z; Deng, Z; Li, J; Liu, T; Peng, Q; Sha, K; Wang, B; Xiao, W; Xie, H; Xu, S; Zhang, Y, 2019) |
| "Our findings suggest thalidomide attenuates the inflammation and represses NF-κB activation in skin, which leads to assumptions that thalidomide may be a new therapeutic agent for rosacea." | 3.91 | Thalidomide ameliorates rosacea-like skin inflammation and suppresses NF-κB activation in keratinocytes. ( Chen, M; Chen, Z; Deng, Z; Li, J; Liu, T; Peng, Q; Sha, K; Wang, B; Xiao, W; Xie, H; Xu, S; Zhang, Y, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M | 1 |
| Xie, H | 1 |
| Chen, Z | 1 |
| Xu, S | 1 |
| Wang, B | 1 |
| Peng, Q | 1 |
| Sha, K | 1 |
| Xiao, W | 1 |
| Liu, T | 2 |
| Zhang, Y | 2 |
| Li, J | 1 |
| Deng, Z | 1 |
| Thompson, BJ | 1 |
| Furniss, M | 1 |
| Zhao, W | 1 |
| Chakraborty, B | 1 |
| Mackay-Wiggan, J | 1 |
| Qian, G | 1 |
| Zhou, C | 1 |
3 other studies available for thalidomide and Rosacea
| Article | Year |
|---|---|
Thalidomide ameliorates rosacea-like skin inflammation and suppresses NF-κB activation in keratinocytes.
Topics: Animals; Antimicrobial Cationic Peptides; Cathelicidins; Cell Line; Chemokines; Humans; Inflammation | 2019 |
An oral phosphodiesterase inhibitor (apremilast) for inflammatory rosacea in adults: a pilot study.
Topics: Administration, Oral; Adult; Aged; Female; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; | 2014 |
Successful treatment of recalcitrant granulomatous rosacea with oral thalidomide and topical pimecrolimus.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Drug Therapy, Combination; Female; Humans; I | 2015 |